Business Context and Reporting Period
This Form 8-K Current Report was filed by AcelRx Pharmaceuticals, Inc. (ACRX) on November 23, 2021, covering events occurring on November 20, 2021. The filing reports the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Board Composition: The Board size was fixed at ten directors, comprising four Class I, three Class II, and three Class III directors.
- Director Appointment: Jill M. Broadfoot was appointed as a Class I director, effective November 20, 2021, serving until the 2024 annual meeting.
- Committee Assignment: Ms. Broadfoot was initially assigned to the Audit Committee.
Guidance, Outlook, and Compensation
The filing contains no guidance, outlook, or management commentary regarding future financial performance or operational risks. Regarding compensation, Ms. Broadfoot received:
- A stock option to purchase up to 30,000 shares of common stock with an exercise price of $0.7192.
- 15,000 restricted stock units.
- Compensation consistent with the Company's Non-Employee Director Compensation Policy.
An indemnification agreement was also executed, requiring the Company to indemnify Ms. Broadfoot to the fullest extent permitted under Delaware law.
Investor Verification Checklist
- Verify the impact of the new Audit Committee member on the company's financial oversight.
- Review the press release (Exhibit 99.1) for additional context on the strategic rationale for the appointment.
- Confirm the total number of outstanding shares and the dilution effect of the 30,000 options and 15,000 RSUs granted.
- Check subsequent filings for any changes to the Board composition or committee assignments.